“Compared to traditional drugs containing factor VIII (a protein whose deficiency is responsible for haemophilia A) and infusions intravenously, the monoclonal antibody administered subcutaneously has the advantage of maintaining stable basic coagulation levels over time. It therefore provides a constant protective level. Ilaria Nichele, hematologist at the Hemorrhagic and Thrombotic Diseases Center of Vicenza, explained the pros and cons of the new subcutaneous drugs for the treatment of haemophilia A, speaking at the online meeting of the Vicenza stage of ‘Articoliamo’, campaign supported by Sobi with the patronage of FedEmo and dedicated to the joint well-being of haemophilic patients.
“However – he specified – with the new subcutaneous drugs we still have to experience hemorrhagic episodes, in the sense that intense bleeding traumas cannot be treated with these drugs, but must be combined with a blood product”.
“Factor VIII administered as needed, however, does not prevent damage. We can prevent them if we infuse it regularly or with prophylaxis – recalled the specialist – and this is why we recommend prophylaxis in childhood and before recognizable joint disease occurs “.